Background: Interferon regulatory factor 6 functions (IRF6) exhibits tumor-suppression in multiple types of cancer. Here, the antitumor properties and pathways involved in the mechanism of IRF6 investigated in cervical cancer.
Methods: Forty-one pairs of cervical cancer specimens and para-carcinoma tissues were collected to evaluate IRF6 expression using immunohistochemical (IHC) staining and miR-587. Effects of miR-587 and IRF6 in the growth of cervical cancer cells explored by MTT test and HeLa tumor mouse xenograft model. Migration and invasion of cervical cancer cells are monitored using transwell test.
Results: Expression of IRF6 in cervical cancer specimens and cell lines were significantly reduced compared with a suitable control group. In addition, the IRF6 expression negatively correlated with miR-587 in cervical cancer tissue. Bioinformatics algorithms and luciferase tests revealed that IRF6 is a potential target of miR-587 and miR-587 mimic transfection cause significant suppression of the IRF6 protein levels in cervical cancer cells. We also found that the antineoplastic properties of IRF6 can be reversed by overexpressing miR-587 in cervical cancer cells. Upregulation of miR-587 correlated with poor overall survival in cervical cancer. In an experiment in vivo silencing of miR-587 induced tumor growth inhibition HeLa, which was associated with upregulation of IRF6 protein in the tumor.
Conclusion: miR-587 represses posttranscriptionally IRF6 protein expression to cancel the antineoplastic activity of IRF6. The miR-587 / IRF6 signaling pathway plays an important role in the development of cervical cancer and serve as a potential therapeutic target for the treatment of cervical cancer.
Interferon-α2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients: a preliminary matched case-control study
a mouse model of SARS-CoV-2 expressing inflammatory role of type I interferon signaling
acute respiratory syndrome-coronavirus 2 (SARS-Cov-2) has led to over 13 million cases of coronavirus disease (COVID-19) with a significant mortality rate. laboratory rat has been a supporter of the development of therapies and vaccines; However, they do not support infection by SARS-CoV virus-2 because of the inability to use the mouse orthologue inclusion of human angiotensin-converting enzyme receptor 2 (hACE2). While hACE2 support infection and pathogenesis of transgenic mice, these mice were limited in availability and are limited to a single genetic background.
Here we report the development of a mouse model of SARS-CoV-2 is based on adeno-associated virus (AAV) -mediated expression of hACE2. These mice support replication of the virus and showed pathological findings were found in 19 patients COVID. In addition, we show that type I interferon does not control the SARS-CoV-2 replication in vivo but is a significant driver of pathological response. Thus, AAV-hACE2 rat models enables rapid deployment for a strong following in-depth analysis of SARS-CoV infection-2 with patient derived virus is authentic in mice genetically diverse backgrounds.
Description: CD14 produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 357 amino acids (16-366a.a.) and having a molecular mass of 38.3kDa. _x000D_ (Molecular size on SDS-PAGE will appear at approximately 40-57kDa)._x000D_ CD14 is expressed with a 6 amino acid His tag at C-Terminus and purified by proprietary chromatographic techniques.
Description: GAPDH Mouse Recombinant produced in E.Coli is a single, non-glycosylated polypeptide chain containing 356 amino acids (1-333a.a.) and having a molecular mass of 38.2kDa.;GAPDH is fused to a 23 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
Description: Bax Mouse Recombinant amino acid 1-171 produced in E.Coli is a single, non-glycosylated polypeptide chain. ;The Mouse Bax is purified by proprietary chromatographic techniques.
Description: Flt3 Ligand produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain (27-189 a.a.) and fused to a 6 aa His Tag at C-terminus containing a total of 169 amino acids and having a molecular mass of 19.3kDa.;Flt3 Ligand shows multiple bands between 18-28kDa on SDS-PAGE, reducing conditions and purified by proprietary chromatographic techniques.
Description: Resistin Mouse is manufactured with signal sequence of phage fd (21aa) and C-terminal fusion of flagTag (10aa). Resistin Mouse Recombinant Flag-Tagged Fusion Protein is 13.7 kDa protein containing 93 amino acid residues of the Resistin Mouse and 31 additional amino acid residues - signal sequence of phage fd, flagTag (underlined).
Description: IL3 Mouse Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 148 amino acids (27-166 a.a.) and having a molecular mass of 16.7kDa (Migrates at 18-28kDa on SDS-PAGE under reducing conditions).;IL3 is expressed with a 6 amino acid His tag at C-Terminus and purified by proprietary chromatographic techniques.
CTSB Mouse, Cathepsin-B Mouse Recombinant Protein, Active
Description: CTSB Mouse Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 330 amino acids (18-339a.a.) and having a molecular mass of 36.4kDa (Molecular size on SDS-PAGE will appear at approximately 28-40kDa)._x000D_ CTSB is expressed with an 8 amino acid His tag at C-Terminus and purified by proprietary chromatographic techniques.
Description: CST3 produced in Sf9 Insect cells is a single, glycosylated polypeptide chain containing 126 amino acids (21-140a.a.) and having a molecular mass of 14.2kDa. (Molecular size on SDS-PAGE will appear at approximately 13.5-18kDa).;CST3 is expressed with a 6 amino acid His tag at C-Terminus and purified by proprietary chromatographic techniques.
CST3 Mouse, Cystatin-C, Recombinant Protein Mouse Active
Description: CST3 Mouse produced in Sf9 Insect cells is a single, glycosylated polypeptide chain containing 126 amino acids (21-140 a.a.) and having a molecular mass of 14.2kDa (Molecular size on SDS-PAGE will appear at approximately 13.5-18kDa).;CST3 is expressed with a 6 amino acid His tag at C-Terminus and purified by proprietary chromatographic techniques.
CST3 Mouse, Cystatin-C Mouse Recombinant Protein, Active
Description: CST3 Mouse produced in Sf9 Insect cells is a single, glycosylated polypeptide chain containing 126 amino acids (21-140 a.a.) and having a molecular mass of 14.2kDa (Molecular size on SDS-PAGE will appear at approximately 13.5-18kDa).;CST3 is expressed with a 6 amino acid His tag at C-Terminus and purified by proprietary chromatographic techniques.
Acrp30 Mouse, Adiponectin Mouse Recombinant Protein, Trimeric form
Description: Trimeric form of Acrp30 Mouse was expressed in HEK293 cells.;The cysteine 39 was replaced with alanine (C39A) 9. mAd-C39A can only form trimer, but not hexamer or HMW form.
Acrp30 Mouse, Adiponectin Mouse Recombinant Protein, His Tag
Description: The Adiponectin Mouse is created as a recombinant protein with a 21 a.a N-terminal fusion of His Tag. The Adiponectin His-Tagged Fusion Protein, produced in E. coli, is a 27.2kDa protein containing 251 amino acid residues of the Acrp30 Mouse, 18-247 amino acids.
Description: Adipose tissue lysate was prepared by homogenization in modified RIPA buffer (150 mM sodium chloride, 50 mM Tris-HCl, pH 7.4, 1 mM ethylenediaminetetraacetic acid, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100, 1% sodium deoxycholic acid, 0.1% sodium dodecylsulfate, 5 μg/ml of aprotinin, 5 μg/ml of leupeptin. Tissue and cell debris was removed by centrifugation. Protein concentration was determined with Bio-Rad protein assay. The product was boiled for 5 min in 1 x SDS sample buffer (50 mM Tris-HCl pH 6.8, 12.5% glycerol, 1% sodium dodecylsulfate, 0.01% bromophenol blue) containing 50 mM DTT.
Toxoplasma encephalitis is an AIDS-defining condition. The decline in CD4 + T cell IFN-γ-producing AIDS is a major factor in silent reactivation of Toxoplasma gondii to replicate the active stage of infection. Therefore, it is important to characterize the CD4-independent mechanisms that limit acute T. gondii infection. We investigated the in vivo regulation of IFN-γ production by CD8 + T cells, DN T cells and NK cells in response to acute T. gondii infection.
Our data suggest that IFN-γ treatment by non-CD4 cells is dependent on both IL-12 and IL-18, and secretion of bioactive IL-18 in response to T. gondii parasite requires sensing inflammasome feasible by multiple redundant sensors in several hematopoietic cell types.
Ricardo
